Evidence for the prognostic value of increased THOR hypermethylation has also been provided for pancreatic cancer [36], glioblastoma, where THOR methylation is a dynamic process during glioma genesis [33], and for prostate cancer, where the possible risk stratification for low and intermediate Gleason cases by THOR hypermethylation has been suggested [34]. This evidence concerns the gene THORLNC and prostate cancer.